arrow
P

Pierre M. Bet

amsterdam public health
H指数:21
被引数:1,684

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stable remission of depression after antidepressant treatment: prevalence and related sociodemographic and clinical characteristics in a longitudinal, real-world cohort
2026-01-210
OAAI
Barriers, facilitators, and implementation strategies for pharmacogenomics in community pharmacies: a cross-sectional survey among local champions in pharmacies and key opinion leaders in pharmacogenomics

社区药房中药物基因组学的障碍、促进因素和实施策略:一项针对药房地方倡导者和药物基因组学关键意见领袖的横断面调查

2025-10-010
OAAI
Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial
2023-06-088
OAAI
Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19

伊马替尼从癌症到新型冠状病毒肺炎的最佳药物再利用的药代动力学和药效学

2023-05-012
OA
Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods

Rivastigmine对ECT引起的晚期抑郁症认知不良反应的影响 (召回研究): 一项针对55岁以上抑郁症患者的多中心,随机,双盲,安慰剂对照,交叉试验: 原理,目标和方法

2022-07-151
OAAI